Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

254 articles with Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

• Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med

  1/20/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conference call for analysts and investors on Thursday, January 21, 2021 at 4:30 p.m. EST

• Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

  1/19/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH)

• Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

  11/16/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the third quarter 2020 and provided a business update. Tenax will share updates related to levosimendan and its recently completed Phase 2 trial for the treatment of patients with pulmonary hypertension and hea

• Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

  11/10/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced that data from the 24-hour open-label portion of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) Study will be presented during the American Heart Association (AHA) Scientific Sessions 2020

• Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results

  11/6/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST.

• Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation

  10/15/2020

  Tenax gains developmental and commercial rights for a fully-developed oral levosimendan formulation in the U.S. and Canada Oral formulation expected to be used in upcoming Phase 3 registration trial

• Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

  10/2/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF will be presented at the upcoming Heart Failure Society of Amer

• Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/1/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 22 nd Annual Global Investment Conference to be held virtually on September 14th-16th. Anthony DiTonno, Chief Executive Officer, is schedule

• Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

  8/31/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF have been accepted for presentation as a Late-Breaking Clinical Trial at this year’s Heart Failure Society of America (HFSA) Annual Scientific Meeting

• Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

  8/17/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update. “The recently completed Phase 2 trial of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) has garnered s

• Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

  7/20/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the expansion of its Board of Directors with the appointment of Steven Boyd and Keith Maher, M.D. Both Directors are from Armistice Capital, LLC, which recently purchased the Com

• Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

  7/6/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 2,523,611

• Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - June 03, 2020

  6/3/2020

  Tenax Therapeutics, Inc. announced that it received notice from The Nasdaq Stock Market, LLC on June 2, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

•  Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  6/2/2020

  Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)   - Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures - Demonstrated a significant improvement with 6-minute walk distance - No significant safety issues. - Management to host conference call and webcast today at

• Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

  4/9/2020

  Tenax Therapeutics, Inc. today announced that the last patient has completed their final visit in the Company’s Phase 2 clinical trial of levosimendan in patient

• Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial

  3/12/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has completed enrollment of their Phase 2 clinical trial of levosimendan.

• Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

  3/12/2020

  Tenax Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 750,000 shares of its co

• Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

  2/21/2020

  Feb. 21, 2020 13:30 UTC MORRISVILLE, N.C.--( BUSINESS WIRE )-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic has joined our scientific advisory board. Tenax CEO

• Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

  10/31/2019

  Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, provided an update on its on-going clinical trial of levosimendan.

• Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference

  8/29/2019

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 21st Annual Global Investment Conference to be held in New York, NY on September 8th-10th.